U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07519356) titled 'A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)' on April 02.
Brief Summary: The primary objective of this study is to assess the 10-year overall survival (OS) of patients with different lymphoproliferative disorders. Secondary objectives include evaluating the comorbidities and fitness of patients and their impact on treatment choices and outcomes. Additionally, the study will examine the effectiveness of various therapeutic regimens, with a particular focus on new treatments, such as chemo-free protocols, targeted drugs, and cell therapies, in order to determine the best treatment sequence for refractory and rela...